Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02726542 · ClinicalTrials.gov registry record · Early Phase 1
Augmenting Growth Hormone to Ameliorate Nonalcoholic Fatty Liver Disease in Adolescents
A Early Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 24
- Enrollment target
NCT02726542: Completed Early Phase 1 study, sponsored by Massachusetts General Hospital.
NCT02726542 is a Early Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02726542, a Early Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
Fatty liver disease is an increasing problem in overweight and obese young adults. The purpose of this study is to test the effect of growth hormone on liver fat in obese young adults ages 18-29y with increased liver fat.
Interventions
- DRUG somatropin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2017-05-03 |
| Est. Completion | 2020-04-02 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02726542
The ClinicalTrials.gov registry entry for NCT02726542 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which somatropin is the first listed.
NCT02726542 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02726542 about?
NCT02726542 is a clinical study titled "Augmenting Growth Hormone to Ameliorate Nonalcoholic Fatty Liver Disease in Adolescents". Fatty liver disease is an increasing problem in overweight and obese young adults. The purpose of this study is to test the effect of growth hormone on liver fat in obese young adults ages 18-29y with increased liver fat.
What is the current status of trial NCT02726542?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2017-05-03. Estimated completion is 2020-04-02.
What interventions are being tested in trial NCT02726542?
The interventions under investigation include: somatropin (DRUG).
Who is sponsoring clinical trial NCT02726542?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.